Feedback / Questions
CAN106 - CANbridge Pharma
https://www.businesswire.com/news/home/20221115006455/en/CANbridge-Pharmaceuticals-Granted-Orphan-Drug-Designation-for-CAN-106-for-the-Treatment-of-Myasthenia-Gravis
Nov 16, 2022
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next